The second month is on the page
The headline is a starter rate. Directly beneath it the pricing block states the amount billed today, the number of months it covers, and the rate that applies afterwards. The advertised saving is the difference between the prepayment and three months at the standing rate, and it is correct.
Seventy-eight of the one hundred and fifty-eight sellers here carry a headline figure that is promotional, introductory, or conditioned on a commitment the number does not disclose. This seller discloses it in the same block. Twenty-three of the one hundred and fifty-eight sellers here carry a recorded introductory rate at all, and printing the standing rate beside it is the version worth having.
The asterisk on the headline is also resolved, one line below, by naming the plan that produces the figure.
The warning letter
The operating entity received an FDA warning letter in February 2026. It is disclosed on this row with its number, its date and a link to the agency's own text, and it does not move the seller's position or score here.
The letter surfaced only because this screen queried the operating company rather than the brand or the domain. Twenty-one of the one hundred and fifty-eight sellers here carry a recorded FDA warning letter.
What it does not say
The pricing block reads that there are no hidden fees, and labels the standing rate a guaranteed fee. Neither sentence answers whether a membership applies. We have recorded the membership position as unstated on that basis; sixty-four of the one hundred and fifty-eight sellers here leave it unstated.
The pharmacy is described as a partner pharmacy rather than named, which puts this seller among the one hundred and twenty-six here that name no compounding pharmacy. No individual clinician is named and no service area is published.
The company is also inconsistent about its own capitalisation on the page that names it, which is trivial in itself and worth noticing on a page whose job is to identify the operator.
MaxLife's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $155/mothe standing Monthly Plan rate; the headline "Starting at $100/mo*" is footnoted "With a Starter Kit Plan", which the pricing block states is billed $300 now for three months and then $155 a month | September 2026source |
| Tirzepatide (compounded) | $195/mothe standing Monthly Plan rate; the $120 headline is the same Starter Kit shape - billed $360 now for three months, then $195 a month | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See MaxLife's current price →Good fit if
- Buyers who want the month-four price printed beside the month-one price.
- Readers who want a prepayment amount and a term stated rather than implied.
- Anyone who checks a seller's advertised saving against its own figures; this one holds.
Look elsewhere if
- Readers who will not buy from a company with a recorded FDA warning letter.
- Buyers who need the compounding pharmacy named.
- Anyone who wants a plain statement about whether a membership applies.
- People who need a service-area list.
How this review was verified
- Read both product pages and the consumer health data privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run that returned a not-found status with zero characters of body text.
- Joined adjacent text nodes before matching prices; the starter block splits the prepayment amount and the renewal rate across separate elements.
- Checked the advertised saving against the two published rates rather than repeating it, and it reconciles.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable with a positive and a negative control in the same pass. The entity query returned a letter to MaxLife Technologies Inc. dba Maxlife, No. 721453, issued 20 February 2026; the letter page was then fetched directly and its recipient block matched the entity and the contact address published on the seller's own site. A minted, non-existent letter path on the same host returned a not-found status in the same run.